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Human thymidylate synthase, a target in cancer chemotherapy, was crystallized from PEG 3350 with 30 mM
ammonium sulfate (AS) in the crystallization medium. The
crystals are isomorphous with the high-salt crystals (2.0 M
AS) and the structure has been solved and refined (R = 22.6%,
Rfree = 24.3%) at 1.8 Å resolution. The high- and low-ASconcentration structures are quite similar, with loop 181–197 is
in the inactive conformation. Also, residues 95–106 and 129–
135 (eukaryotic inserts region) show high mobility as assessed
by poor electron density and high values of crystallographic
temperature factors (residues 1–25 and 108–129 are disordered in both structures). The high mobility of this region
may reflect the situation at physiological ionic strength. Of the
four sulfate ions observed bound at 2.0 M AS, only two are
present at 30 mM AS. The inactive conformation appears to
be stabilized by the side chain of Val3 or a leucine residue
from the disordered regions. The low-salt conditions of these
crystals should be much more suitable for the study of
thymidylate synthase inhibitors, especially those that utilize
sulfate-binding sites to stabilize the inactive conformation of
loop 181–197.

Received 29 September 2004
Accepted 23 February 2005

PDB Reference: thymidylate
synthase, 1ypv, r1ypvsf.

1. Introduction

# 2005 International Union of Crystallography
Printed in Denmark – all rights reserved

622

doi:10.1107/S0907444905005895

Thymidylate synthase (TS) catalyzes the reaction in which the
nucleotide deoxyuridylate (dUMP) is reductively methylated
by the folate co-substrate 5,10-methylenetetrahydrofolate
(CH2H4PteGlu) to form thymidylate (TMP) and dihydrofolate (Humphries & Greenberg, 1958). The enzyme is a dimer
of two identical subunits, which generate an asymmetry upon
substrate/ligand binding (Danenberg & Danenberg, 1979;
Anderson et al., 1999). Substrates are bound in an ordered
manner, with dUMP binding at the active site prior to
CH2H4PteGlu. A cysteine residue (Cys195 in human TS; hTS)
at the active site attacks the 6-position of the pyrimidine base
of the nucleotide, resulting in the formation of a covalent bond
between TS and the nucleotide and activating the 5-position of
the nucleotide for subsequent covalent-bond formation with
the C-11 substituent of CH2H4PteGlu (reviewed by Carreras
& Santi, 1995; Stroud & Finer-Moore, 2003; Finer-Moore et al.,
2003).
The enzyme is the sole source of de novo synthesized
thymidylate and its inhibition leads to apoptosis of rapidly
dividing cells such as cancer cells, an effect sometimes referred
to as thymineless death (Houghton, 1999). This phenomenon
is exploited in therapeutic protocols utilizing TS inhibitors,
such as raltitrexed, pemetrexed or pro-drugs such as 5-fluorouracil that are metabolized to TS inhibitors. The inhibitors are
either nucleotide analogs such as 5-fluorodeoxyuridylate
(FdUMP) or folate analogues and are collectively referred to
Acta Cryst. (2005). D61, 622–627
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as antifolates. The effectivness of TS-directed chemotherapy is
often limited by emerging resistance, which usually arises from
an increase in intracellular TS protein levels by a factor of 2–4
(reviewed in Forsthoefel et al., 2004). Two major mechanisms
leading to increased hTS levels have been proposed. In one
mechanism, the intracellular turnover of hTS protein is
decreased upon formation of inhibitory complexes with drugs
(Kitchens et al., 1999; Forsthoefel et al., 2004). The other
mechanism is related to hTS protein binding to its own mRNA
and inhibiting its translation. The formation of inhibitory
complexes competes with mRNA binding and thus reduces
the translational repression of hTS (reviewed in Chu &
Allegra, 1996).
Human TS differs from bacterial TS in three regions: the
N-terminus of hTS is extended by 28–29 residues and two
insertions of 12 and eight residues are present at positions 117
and 146, respectively, in the human protein (Carreras & Santi,
1995). The crystal structure of hTS has been determined using
crystals obtained at high ammonium sulfate (AS) concentrations (Schiffer et al., 1995; Phan, Steadman et al., 2001). It
showed that active-site loop 181–197 is in a conformation
different from that observed in bacterial TS. Since this
conformation places Cys195, a residue crucial for catalytic
activity, outside the active site, the conformer must be inactive.
Another characteristic feature was that loop 108–129, which
contains one of the eukaryotic inserts, was disordered. There

Table 1
Crystallographic data and refinement statistics for hTS.
Values in parentheses are for the outermost resolution shell.
X-ray source
Detector
Wavelength (Å)
Temperature (K)
No. of frames (high/low-resolution passes)
Oscillation range (high/low-resolution passes) ( )
Crystal-to-detector distance
(high/low-resolution passes) (mm)
Space group
Unit-cell parameters
a (Å)
c (Å)
Volume (Å3)
Mosaicity ( )
Resolution range (Å)
Average I
Total No. of reflections
No. of unique reflections
Completeness (%)
Linear Rmerge in 50.00–3.88 Å shell
Total linear Rmerge† (with 0% rejections)
Square Rmerge
No. of reflections in refinement with (|F|/|F| > 0)
R value‡
Rfree§ (%)
R.m.s.d. bond lengths (Å)
R.m.s.d. bond angles ( )
Ramachandran statistics, residues in
Most favored region (%)
Additionally allowed region (%)
Ligands
No. of water molecules

APS SBC-CAT ID
3  3 mosaic
0.91963
100
126/63
0.5/1.0
180/220
P3121
95.77
81.81
650175
0.49
50.0–1.8 (1.86–1.80)
23114 (708)
181168
37932 (3639)
93.6 (91.2)
0.042
0.060 (0.563)
0.053 (0.487)
35328 [87.2%]
0.226
0.243
0.006
1.4
89.2
10.8
2 sulfate ions
138

P
P
† Rmerge = 100 jIðhÞ  hIðhÞij= IðhÞ, where I(h) is the observed intensity and hI(h)i is
the P
mean intensity
of
reflection
h over all measurements of I(h). ‡ R factor =
P
100 jFo  Fc j= Fo , the sums being taken over all reflections with F/(F) > 2
cutoff. § Rfree = R factor for data that were not included in crystallographic refinement.
4.4% of the reflections were used for calculation of Rfree.

Figure 1
Folding of the active and inactive conformer of hTS. Only one subunit of
the dimer is shown. The constant region is shown in green. Loop 181–197
in the active conformer is shown in purple and in the inactive conformer
in red. Loop 108–129 in the active conformer is shown in blue; this loop is
disordered in the inactive conformer. The location of the active site is
indicated by the positions of dUMP and a folate (raltitrexed). The sulfate
ions present in the inactive conformer are shown in orange and the valine
stabilizing the inactive conformer (perhaps Val3) in yellow.
Acta Cryst. (2005). D61, 622–627

were four sulfate ions bound per subunit. Studies of a truncated version of hTS (Almog et al., 2001) and an inhibitory
complex of hTS with dUMP and raltitrexed (Phan, Koli et al.,
2001) yielded high-resolution structures of hTS with loop 181–
197 in the active conformation. In these structures, determined
at low salt concentration, loop 108–129 was ordered. A
superposition of the active and inactive conformers is shown
in Fig. 1. Intrinsic fluorescence studies of hTS showed that in
solution there is an equilibrium between the active and inactive conformers and that the presence of phosphate or
sulfate ions drives the equilibrium towards the inactive
conformation, while dUMP, a substrate, drives it towards the
active conformation (Phan, Steadman et al., 2001). It was
proposed that the stabilization of the inactive conformation as
a means to achieve hTS inhibition may yield therapeutic
outcomes superior to those of classical active-site-directed
inhibitors as it may not lead to increased levels of TS (Phan,
Steadman et al., 2001; Berger et al., 2004). To facilitate
structure-based design of inhibitors that lock hTS in the
inactive conformation we have crystallized hTS at a low AS
concentration that should allow binding of anionic ligands in
crystal soaking experiments. The low-salt hTS structure is
reported here at 1.8 Å resolution.
Lovelace et al.
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Figure 2
Comparison of the B factors for low-AS and high-AS structures of hTS plotted using the CCP4 program suite (Collaborative Computational Project,
Number 4, 1994). The average B factor in the high-AS structure is lower by 7.1 Å2.

2. Experimental
2.1. Protein expression and crystallization

Recombinant hTS was expressed and
purified as described previously (Phan,
Steadman et al., 2001) with minor modifications. Briefly, the cell-free extract was first
chromatographed on a Q-Sepharose anionexchange column followed by bufferexchange of the active fractions. The
resulting supernatant was then passed
through a Blue Sepharose CL-6B column.
The active fractions were pooled and
analyzed by SDS–PAGE for purity. Crystals
of hTS were grown under low-salt conditions (30 mM ammonium sulfate, 30–40%
PEG 4K, 0.1 M Tris pH 8.5, 20 mM ME)
by sitting-drop vapour diffusion. High-salt
crystals were obtained using the same
buffer and pH but using 38–50% saturated
ammonium sulfate as precipitant and
40 mM phosphate (Phan, Steadman et al.,
2001).
2.2. Data collection and processing

Figure 3
Sulfate-binding region of hTS, located at the junction of three subunits. The subunits in yellow
and green form the physiological dimer; the subunit in red is from crystal contacts. (a) Electron
density in the final 2Fo  Fc map contoured at the 1 level. (b) The position of the additional
sulfate ion present in the 2.0 M AS structure is shown in blue. A fragment of dUMP bound in
the active conformer is shown in purple (Phan, Koli et al., 2001); its phosphate position does not
correspond to any of the sulfate-binding sites in the inactive conformer.
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An hTS crystal was transferred to cryosolvent (mother liquor brought to 10% in
ethylene glycol) for a few seconds and flashfrozen. X-ray diffraction data were
collected at the SBC-CAT ID beamline at
APS, Argonne National Laboratory at a
wavelength of 0.97929 Å. Two passes were
used: one with 0.5 oscillation range and the
other with 1.0 oscillation range. Although
90 of data were collected, the rapid rise in
Rmerge limited the useful data to 126 frames
Acta Cryst. (2005). D61, 622–627
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for the high-resolution scan and 63 frames for the low-resolution scan. The data were indexed and processed with
HKL2000 (Otwinowski & Minor, 1997); processing parameters and statistics are summarized in Table 1.

present in both Fo  Fc and 2Fo  Fc maps and formed
appropriate contacts with the protein molecule. Water molecules that had a B factor above 75 Å2 after refinement were
deleted. The correctness of the structure was evaluated using
PROCHECK (Laskowski et al., 1993).

2.3. Structure determination and refinement

The structure was solved by molecular replacement using
CNS (Brünger et al., 1998) with the structure obtained under
high-salt conditions (PDB code 1hw3; Phan, Steadman et al.,
2001) as the search model. This approach was selected since
the unit cells had c parameters that differed by 1.4 Å. Crystallographic refinement was carried out with iterative combination of interactive graphics utilizing TURBO-FRODO
(Roussel & Cambillau, 1991) and simulated annealing using
CNS. Water molecules were assigned to peaks that were

2.4. Superposition and graphics

Superposition of the protein models was carried out using
the LSQKAB program from the CCP4 package (Collaborative Computational Project, Number 4, 1994). Fig. 1 was
prepared using MOLSCRIPT (Kraulis, 1991) and
RASTER3D (Merritt & Bacon, 1997), Fig. 2 was prepared
with the BPLOT program from the CCP4 package and Figs. 3
and 5 were generated using TURBO-FRODO. Calculations of
the molecular electrostatic potential were carried out with
DELPHI (Rocchia et al., 2001, 2002) and displayed in Fig. 4
with GRASP (Nicholls et al., 1991).

3. Results and discussion

Figure 4
Molecular electrostatic potential of hTS. (a) Active conformer (Almog et
al., 2001; PDB code 1hzw). The arrow points to the region of ordered loop
108–129. (b) Inactive conformer (this report). The arrow points to one of
the bound sulfate ions; the other is buried and not visible.
Acta Cryst. (2005). D61, 622–627

Despite large differences in the composition of the mother
liquors, the high-salt (2.0 M AS) crystals and low-salt (30 mM
AS) crystals of hTS have the same space group P3121 and
similar unit-cell parameters: a = 95.82, c = 83.21 Å and a = 95.77,
c = 81.81 Å, respectively. This indicates that the principal
determinants of crystal packing are similar for both crystallization conditions.
In general, the low-salt crystals of hTS are of similar quality
to the high-salt crystals. Although we report data at the
somewhat higher resolution of 1.8 Å compared with 2.0 Å, this
may reflect progress in beamline instrumentation rather than
the crystal quality. The somewhat higher values of the R
factors (22.6 and 24.3%) are likely to be a result of the
disorder of 16% of the protein. There are some stretches of
electron density that are not interpretable (see below) but
which are likely to contribute to X-ray scattering. A superposition of the high- and low-AS structures yielded average
and r.m.s. displacements of 0.19 and 0.40 Å, respectively. The
largest difference, 5.4 Å, was at Gly52, where a loop was
rebuilt; it is more likely to reflect reinterpretation of better
electron density than a real structural change. A comparison
of the average temperature factors is shown in Fig. 2. The
absolute values of temperature factors may to some degree
depend on the resolution, crystal mosaicity and other parameters of data processing, but the relative distribution of B
factors is more reliable. It shows high similarity except for the
regions adjacent to the disordered fragments of the molecule,
where the B factors are somewhat higher for the low-salt
conditions. This suggests that under physiological conditions,
which are closer to the low-salt crystallization conditions, loop
108–129 is at least as mobile as it is under the high-salt
conditions. This confirms that the disorder/mobility of this
loop correlates with the inactive conformation of loop 181–197
and not with the ionic strength of the solution. This is an
important distinction, since the hTS structures in the active
conformation, the truncation mutant (Almog et al., 2001) and
Lovelace et al.
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the inhibitory complex (Phan, Koli et al., 2001), which had the
loop ordered, were determined at low ionic strength. It was
suggested that the mobility of loop 108–129 may facilitate in
priming hTS for degradation (Berger et al., 2004); thus, the
data presented here are consistent with the hypothesis that the
inactive conformer of hTS is more prone to turnover.
Four sulfate ions were bound per subunit in the high-ASconcentration structure. It was speculated that three of them,
clustered in the vicinity of the active site, may map the positions of mRNA phosphates (Phan, Steadman et al., 2001). The
fourth sulfate ion was located far from the active-site region; it
is not present in the low-salt structure. The cluster of three
sulfate ions in the vicinity of the active site observed at high
AS concentration is reduced to two at low AS. One binding
site is conserved; the position of the other is shifted by about
0.8 Å (Fig. 3). This shows the adaptability of the arginine
residues that line this part of hTS molecule. It should be
indicated that hTS in the active conformation binds only one
phosphate ion (at 50 mM Pi concentration) in a position that
corresponds to the phosphate moiety of the dUMP substrate
(Almog et al., 2001). This position is significantly different
from the binding sites observed in the inactive conformer
(Fig. 3). Thus, the transition from the active to inactive
conformation of loop 181–197 affects the distribution of
surface charges and anion-binding properties. A comparison
of the molecular electrostatic potential of hTS in the active
and inactive conformation is shown in Fig. 4.
Other differences between the high-AS and low-AS structures include the lack of bound glycol, a cryosolvent molecule,
which is replaced by two water molecules in the low-salt
structure. On the other hand, in the low-AS-concentration
structure, clear density is present in a hydrophobic pocket
formed by residues Phe137, Gln138, Phe142, Gly143, Trp182
and Leu187 (Fig. 5). We modeled a valine residue into it, but

leucine is also a possibility. The pocket is only present in the
inactive conformer and the density does not correspond to any
fragment of loop 181–197 in the active conformation. If it is
considered that the 6–29 mutant, an hTS variant missing
residues 6–29, crystallized with loop 181–197 in the active
conformation under very similar crystallization conditions, it
appears likely that the 6–29 deletion affects loop 181–197.
The unconnected valine (or leucine) residue interacts with
loop 181–197 and presumably stabilizes the inactive
conformer. Its position with respect to the loop is shown in
Fig. 1. One interpretation is that this residue is a part of the
N-terminus, which is disordered in all reported crystal structures. There is only one valine, Val3, in the N-terminus and two
leucines, Leu8 and Leu13. Studies of N-terminal deletion
mutants (Forsthoefel et al., 2004) have shown that del6 (an
hTS variant with residues 1–6 deleted) is more stable to
intracellular degradation than the wild-type enzyme. This is
consistent with the hypothesis that the inactive conformer is
more rapidly degraded and that the N-terminus shifts the
active/inactive equilibrium towards the latter. On the other
hand, the first residue of the N-terminus that is not disordered,
Pro26, is on the other side of the molecule (for both subunits),
while the disordered loop 108–129 is in the vicinity. This loop
includes Leu118 and Leu121. Another possibility is that the
density is a fragment of a neighboring molecule, which would
suggest that the crystal lattice shifts the equilibrium towards
the inactive conformer. The closest Pro26 is 31 Å away. The
hydrophobic pocket includes Trp182 and Leu187, residues
from the loop 181–197, but does not contain phosphate/
sulfate-binding sites. Thus, ligands binding in this pocket
should stabilize the inactive conformer without interfering
with mRNA binding.
The crystal form reported here should enable crystal
binding studies of inhibitors stabilizing the inactive conformer
of hTS and may provide lead compounds
for
new
chemotherapeutic
agents
exploiting this novel approach to hTS
inhibition. A modeling study suggested that
a t-butanol molecule may fit well in the
‘Val3’ binding site and a kinetic study
showed that it is an uncompetitive inhibitor
of hTS with a Ki of 88.5 mM (Lovelace,
work to be published). t-Butanol, if it
indeed binds in the predicted site, would fill
only a part of the cavity and appropriate
larger molecules should be stronger inhibitors.

Figure 5
The hydrophobic pocket with a disconnected valine (Val3 in yellow) or leucine (in red) residue.
The upper part of the pocket is formed by residues from loop 181–197. In front there is a
fragment of density which probably represents another part of the same polypeptide region.
This pocket is about 16–18 Å from the sulfate ions and ligand binding in it should stabilize the
inactive conformer and should not interfere with mRNA binding.
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